Abstract Introduction Hydroxycloroquine (HCQ) has been extensively studied for treatment and prevention of coronavirus diseases 2019 (COVID‐19) from the start of the pandemic. Conflicting evidence about its usefulness has begun to accrue. Methods In the face of controversial results about clinical efficacy of HCQ, we performed a rapid systematic review to assess its safety in the framework of COVID‐19 randomized clinical trials. Results Five studies investigating 2291 subjects were included. The use of HCQ was associated with higher risk of adverse event compared with placebo or standard of care: odds ratio 4.57, 95% confidence interval 2.14–9.45. Conclusion Safety profile of HCQ appears to be unsatisfactory when used to treat or prevent COVID‐19, especially in the light of unproved clinical benefit. This rapid systematic reviews described that the odds ratio of any adverse event is more than four‐fold higher in patients receiving hydroxychloroquine compared with placebo in the context of treatment or prevention of SARS‐CoV‐2 infection.
【저자키워드】 COVID‐19, Randomized controlled trials, Hydroxychloroquine, Safety, SARS‐CoV‐2, meta‐analysis, 【초록키워드】 Treatment, coronavirus disease, coronavirus, pandemic, Hydroxychloroquine, clinical trials, systematic review, COVID‐19, adverse event, Patient, Placebo, HCQ, randomized clinical trials, coronavirus diseases, Evidence, Clinical efficacy, Odds ratio, framework, higher risk, 95% confidence interval, subject, clinical benefit, treat, SARS‐CoV‐2 infection, Prevent, Result, described, performed, receiving, appear, 【제목키워드】 Treatment, randomized clinical trial, Hydroxychloroquine, systematic review, SARS‐CoV‐2,